The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia

被引：0

作者：

Zeidan, Amer ^{[1
,2
]}

Esteve, Jordi ^{[3
]}

Kim, Hee-Je ^{[4
]}

Miyazaki, Yasushi ^{[5
]}

Platzbecker, Uwe ^{[6
]}

Schuh, Andre ^{[7
]}

Westermann, Joerg ^{[8
]}

Malek, Kamel ^{[9
]}

Scott, Jeffrey ^{[10
]}

Niolat, Julie ^{[11
]}

Peyrard, Severine ^{[11
]}

Kiertsman, Flavia ^{[10
]}

Stegert, Mario ^{[9
]}

Fenaux, Pierre ^{[12
]}

机构：

[1] Yale Univ, New Haven, CT USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Hosp Clin Barcelona, Barcelona, Spain

[4] Catholic Univ Korea, Catholic Hematol Hosp, Coll Med, Seoul, South Korea

[5] Nagasaki Univ, Nagasaki, Japan

[6] Univ Hosp Leipzig, Leipzig, Germany

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Charite Univ Med Ctr Berlin, Campus Virchow Clin, Berlin, Germany

[9] Novartis Pharma AG, Basel, Switzerland

[10] Novartis Pharmaceut, E Hanover, NJ USA

[11] Novartis Pharma SAS, Rueil Malmaison, France

[12] Hop St Louis, Paris, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

acute myeloid leukemia; clinical trial; immunotherapy; myelodysplasia; AML;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML-187

引用

页码：S188 / S188

页数：1

共 50 条

[1] The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)
Zeidan, Amer M.
Esteve, Jordi
Giagounidis, Aristoteles
Kim, Hee-Je
Miyazaki, Yasushi
Platzbecker, Uwe
Schuh, Andre C.
Sekeres, Mikkael A.
Westermann, Jorg
Xiao, Zhijian
Malek, Kamel
Scott, Jeffrey
Niolat, Julie
Peyrard, Severine
Ma, Fei
Kiertsman, Flavia
Stegert, Mario
Hertle, Sabine
Fenaux, Pierre
Santini, Valeria
BLOOD, 2020, 136
[2] Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program
Zeidan, Amer M.
Al-Kali, Aref
Borate, Uma
Cluzeau, Thomas
DeZern, Amy E.
Esteve, Jordi
Giagounidis, Aristoteles
Kobata, Krissy
Lyons, Roger
Platzbecker, Uwe
Sallman, David A.
Santini, Valeria
Sanz, Guillermo
Sekeres, Mikkael A.
Wei, Andrew H.
Xiao, Zhijian
Van Hoef, Marlies
Nourry-Boulot, Claire
Sadek, Islam
Bengoudifa, Bourras-Rezki
Sachs, Carolin
Sabo, John
Garcia-Manero, Guillermo
BLOOD, 2021, 138
[3] Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program
Zeidan, Amer M.
Al-Kali, Aref
Borate, Uma
Cluzeau, Thomas
DeZern, Amy E.
Esteve, Jordi
Giagounidis, Aristoteles
Kobata, Krissy
Lyons, Roger
Platzbecker, Uwe
Sallman, David A.
Santini, Valeria
Sanz, Guillermo F.
Sekeres, Mikkael A.
Wei, Andrew H.
Xiao, Zhijian
Van Hoef, Marlies
Nourry-Boulot, Claire
Sadek, Islam
Ma, Fei
Iordan, Angelica
Sabo, John
Garcia-Manero, Guillermo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S317
[4] Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study
Brunner, Andrew
Borate, Uma
Esteve, Jordi
Porkka, Kimmo
Knapper, Steve
Vey, Norbert
Scholl, Sebastian
Wermke, Martin
Janssen, Jeroen
Traer, Elie
Chua, Chong Chyn
Narayan, Rupa
Tovar, Natalia
Kontro, Mika
Ottman, Oliver
Xu, Siyan
Sun, Haiying
Naidu, Purushotham
Szpakowski, Sebastian
Zhang, Na
Mohammed, Anisa
Rinne, Mikael
Wei, Andrew
Garcia-Manero, Guillermo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S188 - S189
[5] Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)
Kyo, Taiichi
Yoshida, Noriaki
Kyo, Kouhei
Okatani, Takeshi
Itagaki, Mitsuhiro
Yuasa, Hiromi
Iwato, Koji
Asaoku, Hideki
Katayama, Yuuta
BLOOD, 2010, 116 (21) : 1209 - 1210
[6] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
Brunner, Andrew M.
Esteve, Jordi
Porkka, Kimmo
Knapper, Steve
Vey, Norbert
Scholl, Sebastian
Garcia-Manero, Guillermo
Wermke, Martin
Janssen, Jeroen
Traer, Elie
Loo, Sun
Narayan, Rupa
Tovar, Natalia
Kontro, Mika
Ottmann, Oliver
Naidu, Purushotham
Kurtulus, Sema
Makofske, Jessica
Liao, Serena
Mohammed, Anisa
Sabatos-Peyton, Catherine A.
Rinne, Mikael L.
Borate, Uma
Wei, Andrew H.
BLOOD, 2020, 136
[7] Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating drugs (HMAs) in patients with very high or high risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis after a phase Ib study
Brunner, A.
Porkka, K.
Knapper, S.
Traer, E.
Scholl, S.
Garcia-Manero, G.
Vey, N.
Wermke, M.
Janssen, J.
Narayan, R.
Loo, S.
Tovar, N.
Kontro, M.
Naidu, P.
Pelletier, M.
Steensma, D.
Lewandowski, A.
Zhang, N.
Mohammed, A.
Borate, U.
Wei, A.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 35 - 36
[8] Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Borate, Uma
Esteve, Jordi
Porkka, Kimmo
Knapper, Steve
Vey, Norbert
Scholl, Sebastian
Garcia-Manero, Guillermo
Wermke, Martin
Janssen, Jeroen
Traer, Elie
Chua, Chong Chyn
Narayan, Rupa
Tovar, Natalia
Kontro, Mika
Ottmann, Oliver
Sun, Haiying
Longmire, Tyler
Szpakowski, Sebastian
Liao, Serena
Patel, Anuradha
Rinne, Mikael L.
Brunner, Andrew
Wei, Andrew H.
BLOOD, 2019, 134
[9] Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).
Chen, James Yuhtyng
Johnson, Lisa
McKenna, Kelly Marie
Choi, Timothy S.
Duan, Jiaqi
Feng, Dongdong
Tsai, Jonathan M.
Garcia-Martin, Natalia
Sompalli, Kavitha
Maute, Roy
Vyas, Paresh
Majeti, Ravindra
Takimoto, Chris H. M.
Liu, Jie
Ramsingh, Giridharan
Chao, Mark
Volkmer, Jens-Peter
Weissman, Irving L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Zeidan, Amer M.
Philipp, Jan
Bewersdorf, Philipp
Hasle, Vanessa
Thompson, Ethan G.
de Menezes, Daniel Lopes
Rose, Shelonitda
Boss, Isaac
Fox, Brian
BLOOD, 2021, 138

← 1 2 3 4 5 →